Between February 1988 and August 2008, confirmed BC from a cohort of 112 patients were subtyped according to the hormone receptor status and Her 2 neu overexpression which were determined by immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH). The prognostic value of the BC subtypes for locoregional control (LRC), distant metastases control (DMC), disease free survival (DFS) and overall survival (OS) was investigated using Kaplan-Meier curves and multivariable Cox regression model.
INTRODUCTION
Breast cancer is the most common cancer among women in many countries including Saudi Arabia and poses a major health problem. In Saudi Arabia, there has been a steady increase in breast cancer over a decade [1] . Most of Saudi women with breast cancer are diagnosed relatively at young age and mostly have locally advanced stages and are treated with multimodality approach (neoadjuvant chemotherapy, surgery, adjuvant radiotherapy, chemotherapy and hormonal therapy) with 5 years disease free survival (DFS rates ranging from 29%-40% [2] . Clinical features (young age and premenopausal status), histopathological features (T stage > T3, N1-N3, absence of estrogen and progesterone receptors and overexpression of Her2 neu) have been known as major prognostic features for locoregional control (LRC), distant metastases control ((DMC) and DFS [2] [3] [4] [5] [6] [7] . [8] . Patients with basal subtypes are known to have the worst overall survival, reflected by the abundance of triple negative (ER-negative, PR-negative and ERBB2-negative) tumors followed by patients with cancer subtypes of Her 2 neu [9] . Both these subtypes are also more sensitive to neoadjuvant chemotherapy than luminal A and B subtypes [10] . In addition, among the luminal subtype of tumors, the luminal B subtype has been found less responsive to hormonal therapy and has a less favorable treatment outcome as compared to luminal A subtype [11] .
However molecular classification and its prognostic significance in Saudi women with breast cancers have not been studied. We aimed to evaluate the frequency of these molecular subtypes and their impact on treatment outcomes in Saudi women with breast cancer.
MATERIALS AND METHODS
After the approval from Institutional Ethical Review Board (IRB) committee, 112 patients with breast cancer were treated between February 1988 and August 2008 with BCS and MRM followed by adjuvant chemotherapy and radiotherapy and comprised the study population. Inclusion criteria were; (a) histopathological confirmed breast cancer, (b) T1-T4, N0-N2, (c) underwent BCS or MRM +/-adjuvant hormonal, chemotherapy and radiotherapy. Exclusion criteria were; (a) presence of distant metastasis, (b) neoadjuvant chemotherapy and (c) inflammatory or inoperable tumors.
Breast Cancer Pathological Specimens
After surgery, breast cancer specimens were fixed in 10% formalin overnight and were examined to evaluate the, gross size, histopathological type, grade, presence or absence of lymphovascular (LVSI) invasion, lymph nodes and retrieved and involved number. Immunohistochemical (IHC) analysis was performed to classify the breast cancers according to IHC-based breast cancer subtypes and also fluorescence in situ hybridization (FISH) was performed.
Molecular Sub-Typing
Estrogen receptors (ER), progesterone receptors (PgR) and Her 2 neu overexpression status was performed by IHC analysis with antibodies against the ER (Dako, Denmark) and PR (BioGenex, San Ramon, CA). Cut off value of 1% for both receptors was considered ER or PR presence as per to institutional protocol [7] .
Her 2 neu overexpression was checked for IHC equivocal cases using a HER2 DNA Probe Kit (Abbott) according to the manual instructions. Her 2 neu was considered positive when the HER2/CEP 17 ratio was 2.1 or higher [10] . 
Clinical Variables
Additional clinical features including age, menopausal status, associated co-morbidities, initial tumor size on physical, mammography and sonography examination, laterality and location of primary tumor were studied. Surgery was performed either wide local excision or MRM with axillary lymph node dissection.
Statistical Analysis
The primary endpoints were frequency of molecular subtypes, correlation with clinical and histopathological features, locoregional control (LRC), distant metastases control (DMC), disease free survival (DFS) and overall survival (OS) according to breast cancer subtypes. The times to last follow up evaluation, appearance of local relapse and death were calculated from date of starting treatment. DFS was defined as the duration between the entry date and the date of documented disease reappearance, death from cancer and/or last follow-up (censored). OS was defined as the duration between the entry date and the date of patient death or last follow-up (censored). Probabilities of LRC and DMC, DFS and OS were determined with the Kaplan-Meier method. The comparisons between various endpoints were performed using log rank test and Cox proportional hazard analysis. Univariate and multivariate analyses were also performed for different prognostic factors for LRC, DMC, DFS and OS. All statistical analyses were performed using the computer program SPSS version 16.0.
RESULTS
Median follow up period was 9 years (range: 5-17). Patients' characteristics according to molecular breast cancer subtypes were shown in Table 1 . Predominant breast cancer subtypes were luminal A (36 patients; 32.2%) and Her2 neu (36 patients; 32.2%). Basal like subtype was least frequent (11 patients; 9.8%). In four patients (3.6%) there was bilateral breast cancer at the time of diagnosis. Majority of cohort (57 patients; 79.6%) had left side breast cancer and outer lower quadrant was common site of tumor location (50 patients; 45.9%) followed upper outer quadrant (30 patients; 27.5%). Mean mammography size of tumor was 3.9 cm (range: 1-7; SD 2.3)). Mean baseline CA15.3 level was 31.1 units/ml (range: 1-94.3; SD 23.9).
Clinical Characteristics

Histopathological Characteristics
Mean pathological tumor size was 3.4 cm (range: 1-10; SD 2.4) and infiltrating ductal carcinoma (IDC) was predominant histopathological variant seen in 95 patients (88.0%). Majority of tumors were moderately differentiated (GII) (68 patients; 60.7%). According to marginal status, 77 patients (68.8%) had negative margins.
Treatment Characteristics
Majority of patients had MRM (77 patients; 71.3%) followed by BCS in 31 patients (28.7%). Mean axillary retrieved lymph nodes were 14.1 (2-42) after axillary dissection and sentinel node dissection.
Total 70 patients (62.5%) received adjuvant chemotherapy which was given within 5-6 weeks (range: 3-11) of surgery. Adjuvant chemotherapy protocols were as; CMF (18.6%), AC followed Paclitaxal (32.9%), FAC (32.9%), TAC (5.9%), AT (5.7%), FAC+TAC (4%).
Total 89 patients (83.0%) received local radiation therapy which was started 22 weeks (18) (19) (20) (21) (22) (23) (24) (25) (26) after the surgery and 3-5 weeks after the completion of chemotherapy. For BCS patients, whole breast radiation therapy was delivered in 2Gy fractions to mean total mean dose of 50 Gy (45-64) and for MRM patients, chest wall radiation therapy was given in 2 Gy fractions to mean total dose 50Gy (50-60). For positive axillary nodes, supra-clavicular fields were used and given mean total dose of 45 Gy (42.5-50). All patients were treated using three dimensional conformal radiation therapy (3DCRT) and on multileaf collimator (MLC) assisted linear accelerator.
Sixty three patients were given hormonal therapy in form of tamoxifen (46.4%), letrozole (9.8%) and sequential regimen in 9.8%. Mean duration of hormonal therapy was 5.5 years (range; 3.5-7.2).
Locoregional Recurrence, Distant Control and Overall Survival
Total ten locoregional recurrences (8.93%) were seen among 112 breast cancer patients. Four (40%) LRR occurred at scar site and 6 LRR ((60%) were seen in ipsilateral axilla and supraclavicular regions. Median time of LRR was 3.6 years (range: 2.73-5.1). The actual LRC rates at 5 and 10 years were 86.4% (Fig. 1) . Distant metastases were documented in 29 patients at 5 years and 37 patients at 5 and 10 years with 5 and 10 actual DMC rates of 63% (95% CI: 57-79.0) and 56.7% (95% CI:54 -65.2) respectively (Fig. 2) . Actual 5 and 10 years DFS rates were 77.4% and 66.4% respectively (Fig. 3) . Five and 10 years OS rates were 74.2% and 68.7% respectively. According to breast cancer subtypes, there was no difference between LRR, however luminal A subtypes had better DMC and DFS rates and Basal like subtype was related to poor DMC and DFS (Figs.  4-6 ). (Table 2A) . For DMC, in addition to age less than 45 years and premenopausal status, breast cancer subtypes were found important prognostic factors (Table 2B, 2C). Fig. (2) . Cumulative distant metastases control in study cohort. Fig. (3) . Cumulative disease free survival in study cohort. Fig. (4) . Locoregional control according to breast cancer subtypes. 
DISCUSSION
In past decade, a molecular classification system was proposed to divide breast cancers into subtypes owing to response to optimal treatment and it has become widely used these days [12] . However molecular classification has not been studied in Saudi women with breast cancer. In present study, the pattern of breast cancer subtypes, association with clinical and histopathological features and LRR, DMC, DFS and OS according to breast cancer subtypes in Saudi women were studied.
Key findings in present study were; a.
There was similarity in clinical and histopathological features of luminal A and luminal B subtypes but difference in DFS rates (33% increased DFS associated with luminal A), which is consistent with results of other similar studies [13, 14] .
b. Her 2 neu over-expression was seen in 32.2%, which is much higher than reported by western studies [15] .
c. Basal like subtype was least frequent but associated with worst DMC and DFS rates as compared to other subtypes which are consistent with results of reported literature [16] . However, in terms of response to chemotherapy, many studies in which breast cancer patients were treated with neoadjuvant anthracyclinebased chemotherapy have shown higher response rates in basal subtypes as compared to luminal subtypes [10, 17] . Adjuvant non anthracycline-based chemotherapy had minimal impact on basal subtypes [18] .
d. Breast cancer subtypes were not found significant prognostic factor for LRC rates.
Our study can criticized for (a) low sample size, (b) Ki-67 index was not performed to assess tumor cell proliferation [19] and (c) lack of DNA ploidy assessment, which have been known as important prognostic factors for DMC and DFS rates [20] , which shall be addressed in future studies of Saudi women with breast cancer.
In conclusion, frequency pattern, clinicopathological characteristics and treatment outcomes of breast cancer subtypes in Saudi women are consistent with other related studies; however the Her 2 neu overexpression is more in Saudi women. Breast cancer subtype classification may be helpful if considering neoadjuvant chemotherapy (basal subtype more responsive) and hormonal therapy (luminal B less responsive). 
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